These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 10604342

  • 21. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS.
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R.
    BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
    [Abstract] [Full Text] [Related]

  • 31. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J, Maricić A, Valencić M, Oguić R, Krpina K, Protić A, Ivancić A, Bobinac M, Fuckar D, Vojniković B.
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The impact of osteoporosis in men treated for prostate cancer.
    Oefelein MG, Resnick MI.
    Urol Clin North Am; 2004 May; 31(2):313-9. PubMed ID: 15123410
    [Abstract] [Full Text] [Related]

  • 35. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.
    Cancer; 2004 Aug 01; 101(3):541-9. PubMed ID: 15274067
    [Abstract] [Full Text] [Related]

  • 36. Incidence and risk factors for low trauma fractures in men with prostate cancer.
    Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV.
    Bone; 2008 Sep 01; 43(3):556-60. PubMed ID: 18585119
    [Abstract] [Full Text] [Related]

  • 37. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.
    J Clin Oncol; 2006 Aug 20; 24(24):3979-83. PubMed ID: 16921050
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.